Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dendritic cells

Phase 2Biologic

IInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Dendritic cells is one of 45 biologic programs targeting Glioma. It is currently in Phase 2.

2

Indications

7

Total Trials

1

Active Trials

44

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Liver NeoplasmsActive, not recruiting

GliomaPreclinical

Active, not recruiting

Liver NeoplasmsPhase 2

Active, not recruiting

Competition

Competitive Landscape

103 competitors in Glioma

#DrugCompanyPhaseTrials

Avastin

Paraplatin

Voranigo

Ojemda

Day One Biopharmaceuticals

Camptosar

Verzenio

Lynparza

Imfinzi

Lenvima

Oncovin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Liver Neoplasms

NCT07726329

Clinical

Trials by Indication[1]

Melanoma1 trial

Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients

Completed·RRadboud University Medical Center·Phase 1/2·NCT00847106·15 enrolled

Dendritic Cell1 trial

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT01171469·8 enrolled

Bladder Cancer1 trial

Treatment of Recurrent Bladder Cancer With Dendritic Cells

Completed·IInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus·Phase 2·NCT04184232·17 enrolled

Breast Cancer1 trial

Immunogenicity and Safety of DCs in Breast Cancer

Completed·FFundación Salud de los Andes·Phase 1/2·NCT03450044·15 enrolled

Glioma1 trial

Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas

Unknown status·HHebei Yanda Hospital·N/A·NCT02771301·30 enrolled

2 more indications

Advanced Solid Tumours1 trial

Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults

Completed·—·Phase 1/2·NCT02496520·6 enrolled

Liver Neoplasms1 trial

A Phase II Trial, Sequential Treatments of Dendritic Cell Vaccination Followed by Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma

Active, not recruiting·CChang Gung Memorial Hospital·Phase 2·NCT07726329·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Dendritic cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dendritic cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dendritic cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Related News